Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib + VIC-1911 in Lenvatinib-unresponsive/resistant HCC
NCT05718882Terminated
- Sponsor
- Renji Hospital
- Start
- Aug 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of TAS-119 in hepatocellular carcinoma (HCC), sponsored by Renji Hospital. Primary endpoint: Progression-Free Survival at 6 months. Started Aug 2023; status: terminated.
02
Drugs
TAS-119
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05718882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05718882.